Compare Stocks → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ASLNNASDAQ:COCPNASDAQ:CYCNNASDAQ:NLTX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASLNASLAN Pharmaceuticals$0.46-11.7%$0.61$0.39▼$4.69$7.44M1.45994,543 shs11.36 million shsCOCPCocrystal Pharma$1.52-0.7%$1.49$1.33▼$3.29$15.46M1.3413,622 shs9,707 shsCYCNCyclerion Therapeutics$2.97-15.1%$3.10$1.75▼$6.75$8.05M1.843,246 shs3,541 shsNLTXNeoleukin Therapeutics$30.49-3.5%$37.17$2.03▼$14.36$286.55M1.1150,104 shs82,724 shs20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASLNASLAN Pharmaceuticals-11.13%-9.95%-30.32%-16.36%-88.57%COCPCocrystal Pharma-0.65%+8.57%-0.65%+3.40%-38.71%CYCNCyclerion Therapeutics-15.14%-13.66%-2.62%-13.91%-50.17%NLTXNeoleukin Therapeutics0.00%+118.41%-38.87%+0.49%+79.35%top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (Ad)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution…MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationASLNASLAN Pharmaceuticals2.4088 of 5 stars3.55.00.00.01.60.80.6COCPCocrystal Pharma2.5725 of 5 stars3.53.00.00.00.01.71.3CYCNCyclerion TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ANLTXNeoleukin TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASLNASLAN Pharmaceuticals3.00Buy$11.332,390.84% UpsideCOCPCocrystal Pharma3.00Buy$10.00557.89% UpsideCYCNCyclerion TherapeuticsN/AN/AN/AN/ANLTXNeoleukin TherapeuticsN/AN/A$30.00-1.61% DownsideCurrent Analyst RatingsLatest CYCN, NLTX, ASLN, and COCP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/15/2024ASLNASLAN PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.004/4/2024COCPCocrystal PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.003/20/2024COCPCocrystal PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.003/18/2024ASLNASLAN PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$17.00 ➝ $9.003/13/2024ASLNASLAN PharmaceuticalsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$15.00 ➝ $10.00(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASLNASLAN Pharmaceuticals$12M0.62N/AN/A($0.81) per share-0.56COCPCocrystal PharmaN/AN/AN/AN/A$2.59 per shareN/ACYCNCyclerion Therapeutics$1.62M4.97N/AN/A$4.62 per share0.64NLTXNeoleukin TherapeuticsN/AN/AN/AN/A$11.08 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASLNASLAN Pharmaceuticals-$44.22M-$2.74N/AN/AN/AN/A-8,454.87%-95.72%4/26/2024 (Estimated)COCPCocrystal Pharma-$17.98M-$1.99N/AN/AN/AN/A-59.62%-54.62%5/20/2024 (Estimated)CYCNCyclerion Therapeutics-$5.26M-$5.51N/A∞N/AN/A-111.79%-74.10%5/9/2024 (Estimated)NLTXNeoleukin Therapeutics-$57.56M-$3.11N/A∞N/AN/A-37.22%-30.91%N/ALatest CYCN, NLTX, ASLN, and COCP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/12/2024Q4 2023ASLNASLAN PharmaceuticalsN/A-$0.78-$0.78-$0.78N/AN/A3/28/2024Q4 2023COCPCocrystal Pharma-$0.57-$0.44+$0.13-$0.44N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASLNASLAN PharmaceuticalsN/AN/AN/AN/AN/ACOCPCocrystal PharmaN/AN/AN/AN/AN/ACYCNCyclerion TherapeuticsN/AN/AN/AN/AN/ANLTXNeoleukin TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASLNASLAN PharmaceuticalsN/A1.841.84COCPCocrystal PharmaN/A8.928.92CYCNCyclerion TherapeuticsN/A3.853.85NLTXNeoleukin TherapeuticsN/A15.3315.33OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASLNASLAN Pharmaceuticals58.82%COCPCocrystal Pharma6.72%CYCNCyclerion Therapeutics75.62%NLTXNeoleukin Therapeutics52.37%Insider OwnershipCompanyInsider OwnershipASLNASLAN Pharmaceuticals4.69%COCPCocrystal Pharma25.06%CYCNCyclerion Therapeutics13.10%NLTXNeoleukin Therapeutics1.58%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableASLNASLAN Pharmaceuticals3516.35 million15.58 millionOptionableCOCPCocrystal Pharma1210.17 million7.62 millionNot OptionableCYCNCyclerion Therapeutics12.71 million2.36 millionNo DataNLTXNeoleukin Therapeutics79.40 million9.25 millionOptionableCYCN, NLTX, ASLN, and COCP HeadlinesSourceHeadlineNeurogene concludes merger deal with Neoleukin Therapeuticspharmaceutical-technology.com - December 20 at 9:16 AMIs Neoleukin Therapeutics (NASDAQ:NLTX) In A Good Position To Invest In Growth?finance.yahoo.com - December 20 at 9:16 AMNeoleukin Therapeutics Announces 1-for-4 Reverse Stock Splitfinance.yahoo.com - December 15 at 12:06 AMNeoleukin Therapeutics Stock (NASDAQ:NLTX) Dividends: History, Yield and Datesbenzinga.com - December 4 at 11:08 PMPre-market Movers: ORTX, CMBM, GROM, RSVR, FEMY…markets.businessinsider.com - October 5 at 8:10 AMNeoleukin Therapeutics, Inc.: Neoleukin Therapeutics Announces 1-for-5 Reverse Stock Splitfinanznachrichten.de - September 26 at 8:11 AMNeoleukin Thera (NASDAQ: NLTX) should be up 500% - it’s actually up 7%dhakatribune.com - September 26 at 8:11 AMNeoleukin Therapeutics Announces 1-for-5 Reverse Stock Splitfinance.yahoo.com - September 22 at 8:21 AMInvesting in Neoleukin Therapeutics Inc. [NLTX]: What You Must Knowknoxdaily.com - August 21 at 5:51 PMNeoleukin Therapeutics Recent Insider Activitybenzinga.com - August 18 at 4:56 PMBAKER BROS. ADVISORS LP Reduces Stake in Neoleukin Therapeutics Incfinance.yahoo.com - August 18 at 4:56 PMSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AMNB, CCF, NLTX, SCUmarkets.businessinsider.com - August 8 at 8:05 AMSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AJX, DEN, FREQ, NLTXmarkets.businessinsider.com - August 1 at 6:57 AMRedmile Group, LLC Boosts Stake in Neoleukin Therapeutics Incfinance.yahoo.com - July 28 at 11:02 AMMoore Kuehn Encourages AMNB, SCU, NLTX, and PRDS Investors to Contact Law Firmbenzinga.com - July 26 at 7:36 PMAnalysts review Neoleukin Therapeutics Inc.’s ratingknoxdaily.com - July 26 at 7:36 PMALERT: The M&A Class Action Firm Continues Investigating the Merger – SCU, NLTX, HCCI, CCFkentuckytoday.com - July 24 at 11:32 PMBaker Bros. Advisors Now Owns 19.99% of Neoleukin Therapeutics247wallst.com - July 24 at 1:31 PMAn Analysis of Neoleukin Therapeutics Inc. (NLTX)’s Potential Price Growthknoxdaily.com - July 19 at 11:36 AMNeurogene and Neoleukin enter definitive merger agreementpharmabiz.com - July 19 at 6:36 AMNeurogene, Neoleukin Announce Planned Mergermarkets.businessinsider.com - July 19 at 6:36 AMNeurogene, Neoleukin Merging to Advance Gene Therapies for Neurological Diseasesprecisionmedicineonline.com - July 18 at 10:54 PMUniv. of Washington spinout Neoleukin Therapeutics merging with New York City startupmsn.com - July 18 at 5:54 PMNeoleukin Therapeutics, Inc.: Neurogene and Neoleukin Announce Definitive Merger Agreementfinanznachrichten.de - July 18 at 12:53 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsASLAN PharmaceuticalsNASDAQ:ASLNASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal antibody that targets the IL-13 receptor a1 subunit which is being developed for the treatment of atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune diseases. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.Cocrystal PharmaNASDAQ:COCPCocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.Cyclerion TherapeuticsNASDAQ:CYCNCyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.Neoleukin TherapeuticsNASDAQ:NLTXNeoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.